WHIPgroup obtained issuance of U.S. Patent No. 10,143,555 for its client Oxford Performance Materials, Inc. for Customized Implants for Bone Replacement after the examiner initially rejected claims as being anticipated or obvious over other references. The patent covers the clients OSTEOFAB® implants which are produced from polyetherketoneketone (PEKK) using a proprietary 3D printing process. In one commercial use, the OsteoFab® Patient Specific Cranial Device (OPSCD) is intended for the replacement of bony voids in the cranial skeleton. The OPSCD is constructed with the use of the patient’s CT imaging data and computer aided design to determine the dimensions of each implant. The device is then manufactured via the OsteoFab® 3D printing laser sintering process. The OPSCD is attached to native bone with commercially available cranioplasty fixation systems and is a non-load bearing, single use device that is sterilized at the healthcare facility using validated steam sterilization cycles.
By: Benjamin N. Luehrs Generic forum selection clauses in patent license agreements can prevent licensees from trying to invalidate licensed patents at the United States Patent and Trademark Office (USPTO). A recent Federal Circuit Opinion, [Read More…]
WHIPgroup obtained another patent allowance just by filing an Appeal Brief. The application relates to a medical shaft instrument having a force transmission element that provides torsional and axial rigidity. The Examiner had rejected the [Read More…]
By Patrick D. Duplessis These days it seems almost every article or news report about self-driving vehicles (SDVs) includes the prophecy that the automobile will soon resemble a “smartphone on wheels.” That oft-repeated phrase alludes [Read More…]